<DOC>
	<DOCNO>NCT02821182</DOCNO>
	<brief_summary>We hypothesize combine anti-PD1 treatment radiotherapy might result improved clinical response rate PFS compare anti-PD1 treatment monotherapy . The current phase II trial aim explore suggest benefit combination aim improve local distant tumour response exploit pro-immunogenic effect radiotherapy addition anti-PD1 treatment .</brief_summary>
	<brief_title>A Phase II Trial Stereotactic Body Radiotherapy With Concurrent Anti-PD1 Treatment Metastatic Melanoma .</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Before patient registration , write informed consent must give accord ICH/GCP , national/local regulation . Histologically confirm diagnosis melanoma At least 3 extracranial measurable metastatic lesion per RECIST v1.1 . All radiology study must perform within 28 day prior registration First line antiPD1 treatment . Karnofsky Performance status &gt; 60 Age 18 year old Female participant childbearing potential must willing use 2 method birth control surgically sterile , abstain heterosexual activity course study 120 day last dose study treatment Female participant breastfeed plan breastfeed instructed discontinue nursing treatment . Male participant must agree use adequate method contraception start first dose study therapy 120 day last dose study treatment Demonstrate adequate organ function define follow : AST ALT ≤2.5 X ULN ≤5 X ULN liver metastases Serum total bilirubin ≤1.5 X ULN direct bilirubin ≤ULN patient total bilirubin level &gt; 1.5 ULN Serum creatinine ≤1.5 X ULN Absolute neutrophil count &gt; 1,000 /mcL Platelets &gt; 75,000 /mcL Hemoglobin &gt; 9 g/dL &gt; 5.6 mmol/L No history active autoimmune disease require systemic treatment within past 3 month document history clinically severe autoimmune disease , syndrome require systemic steroid immunosuppressive agent Prior malignancy : Subjects another malignancy diseasefree 5 year , history completely resect nonmelanomatous skin carcinoma successfully treat situ carcinoma No evidence interstitial lung disease No uncontrolled central nervous metastasis and/or carcinomatous meningitis . No prior radiotherapy interfere SBRT . No concomitant therapy IL2 , interferon , immunotherapy regimen , chemotherapy , immunosuppressive agent chronic use systemic corticosteroid . No active infection require systemic therapy No known history human immunodeficiency virus ( HIV ) No know active Hepatitis B Hepatitis C Did receive live vaccine within 30 day prior start study treatment No mental condition render patient unable understand nature , scope possible consequence study Patient unlikely comply protocol ; i.e . uncooperative attitude , inability return followup visit , unlikely complete study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>